Efficacy and safety of arteriovenous sequential tirofiban in the treatment of acute cerebral infarction
Objective To investigate the efficacy and safety of arteriovenous sequential tirofiban in the treatment of acute cerebral infarction.Methods The clinical data of 134 acute cerebral infarction patients without major arterial occlusion trea-ted with tirofiban during the time window of thrombolysis in Zhengzhou Central Hospital Affiliated to Zhengzhou University from June 2018 to February 2022 were retrospectively analyzed.80 patients with National Institutes of Health Stroke Scale(NIHSS)scores ranging from 5 to 16 were selected and divided into observation group(superselective tirofiban perfusion via arterial catheterization with sequential intravenous pumping of tirofiban,i.e.arteriovenous and sequential application of tiro-fiban,44 cases)and control group(direct intravenous pumping of tirofiban,36 cases).The NIHSS score,effective rate,bleeding rate,and mortality rate of two groups of patients at 7 days and 14 days after treatment were evaluated,and relevant factors for a good prognosis at 90 days were analyzed.Results There was no statistically significant difference in NIHSS scores between the observation group and the control group on 7 days and 14 days after treatment(P>0.05).The effective rate of the observation group was significantly higher than that of the control group(84.1% vs 63.9%),and difference be-tween the two groups was statistically significant(χ2=4.310,P=0.038).No obvious bleeding,death events and adverse drug reactions occurred in the two groups,and no surgical related complications occurred in the observation group.A binary logistic regression analysis with a 90-day prognosis showed that a good prognosis was associated with sequential use of tirofi-ban in the arteries and veins(odds ratio[OR]=3.082,95% confidence interval[CI]was[1.025,9.263],χ2=4.017,P=0.045)and baseline NIHSS score(OR=1.230,95% CI[1.027,1.475],χ2=5.036,P=0.025).Conclusion For acute cerebral infarction patients without major arterial occlusion at the hyperthrombolysis time window and a baseline NIHSS score of 5 to 16,arteriovenous sequential application of tirofiban can improve the long-term prognosis of patients and has val-uable clinical applications.
万方数据
维普
